GILD
Bullish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Gilead Sciences, Inc.
- Nom
- Gilead Sciences, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NASDAQ
- Capitalisation
- $194.9B
- Employés
- 17,000
- PDG
- Daniel O'Day
- Site web
- https://www.gilead.com
- Marché
- ABBVAZNGSKJNJLLYMRK
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 48 000 titres (~7 098 006,30 $ US)
- Insiders
- O''''''''Day Daniel PatrickWELTERS ANTHONY
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,864,148
Avg sell (VWAP, 90d window) $145.54 vs last close $158.69 (+9.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$5,864,148 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $918,427,611/day · 20d vol
- Last synced
-
2026-10-27 06:51:29
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Dickinson Andrew D | Sell · S · 10b5-1 | 3,000 | $156.22 | $468,660 | Form 4 |
| 2026-10-15 | Mercier Johanna | Sell · S · 10b5-1 | 3,000 | $156.22 | $468,660 | Form 4 |
| 2026-10-01 | O'Day Daniel Patrick | Sell · S · 10b5-1 | 3,000 | $148.63 | $445,880 | Form 4 |
| 2026-09-15 | Dickinson Andrew D | Sell · S · 10b5-1 | 3,000 | $145.29 | $435,870 | Form 4 |
| 2026-09-15 | Mercier Johanna | Sell · S · 10b5-1 | 600 | $145.29 | $87,174 | Form 4 |
| 2026-09-01 | O'Day Daniel Patrick | Sell · S · 10b5-1 | 5,408 | $149.38 | $807,856 | Form 4 |
| 2026-08-26 | WELTERS ANTHONY | Sell · S · 10b5-1 | 6,880 | $148.82 | $1,023,900 | Form 4 |
| 2026-08-20 | Bluestone Jeffrey | Sell · S · 10b5-1 | 335 | $146.26 | $48,997 | Form 4 |
| 2026-08-17 | Dickinson Andrew D | Sell · S · 10b5-1 | 3,000 | $138.36 | $415,080 | Form 4 |
| 2026-08-17 | Mercier Johanna | Sell · S · 10b5-1 | 11,470 | $138.04 | $1,583,265 | Form 4 |
| 2026-08-03 | O'Day Daniel Patrick | Sell · S · 10b5-1 | 600 | $131.34 | $78,806 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2024-05-10 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-05-10 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-05-10 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-07-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-05-06 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-05-06 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-01-27 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-06-06 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-14 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-03-31 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-10 | Carol Devine Miller | Purchase | $1,001 - $15,000 |
| 2025-03-07 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-12-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2023-05-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-09 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-11-10 | Carol Devine Miller | Sale (Partial) | $15,001 - $50,000 |
| 2021-09-01 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2021-04-09 | Sara Jacobs | Sale (Full) | $15,001 - $50,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-01-21 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-09-23 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2020-09-01 | Ed Perlmutter | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-15 | Ed Perlmutter | Purchase | $1,001 - $15,000 |
| 2020-07-08 | Roger Wayne Marshall | Sale (Full) | $1,001 - $15,000 |
| 2020-06-29 | William R. Timmons | Sale (Full) | $1,001 - $15,000 |
| 2020-05-07 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-05-05 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-05-04 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2020-02-07 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-21 | Mikie Sherrill | Purchase | $1,001 - $15,000 |
| 2019-12-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-10-25 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2019-09-19 | Bill Flores | Purchase | $1,001 - $15,000 |
| 2019-05-13 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2019-05-08 | Bill Flores | Sale (Full) | $1,001 - $15,000 |
| 2019-04-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-03-25 | Bill Flores | Purchase | $1,001 - $15,000 |
| 2019-03-19 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2019-01-04 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2018-12-21 | Greg Gianforte | Purchase | $15,001 - $50,000 |
| 2018-11-26 | John Yarmuth | Sale (Full) | $1,001 - $15,000 |
| 2018-07-17 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2017-07-17 | John Henry Rutherford | Purchase | $1,001 - $15,000 |
| 2017-04-17 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2017-04-04 | Gary James Palmer | Purchase | $1,001 - $15,000 |
| 2017-02-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
Signal
Bullish signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Gilead combines robust financial health (net margin 28.9%, ROE 37.5%, debt-to-EBITDA 1.28) with a confirmed M&A catalyst — the acquisition of oral IL-23R inhibitor HCXT-2001 — that meaningfully expands its IBD pipeline.
The first sentence of the analysis written for GILD on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.9M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.9M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 1.55 · operating margin 40%
Suggested stop 142.39, nearest stored support minus 0.5 ATR(10.3% under the last close). Reward/risk to the next stored resistance is 0.11. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Looking beyond Wall Street''s top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company''s potential performance for the quarter ended September 2026.
- 2026-10-26 Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake Citizens Financial Group Inc. RI boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 52.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,063 shares of the biopharmaceutical company''s stock after purchasing an additional
- 2026-10-25 Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? Amgen and Gilead pay forward dividend yields above 2%. Gilead has a lower dividend payout ratio, but Amgen is generating stronger sales growth.
- 2026-10-23 The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors'' medications. In many cases, these presc.
- 2026-10-22 Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company. Key Highlights HCXT-2001 is an investigational, clinical-stage, oral, macrocyclic peptide inhibitor of IL-23R with an extended half-life, offering a potentially differentiated approach to oral.
- 2026-10-22 Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-10-22 Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management acro.
- 2026-10-22 BioNTech, Gilead to test drug combination in advanced breast cancer trial BioNTech, Gilead to test drug combination in advanced breast cancer trial
- 2026-10-22 Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? Both of these ETFs look the part, but only one is truly the better buy for investors.
- 2026-10-21 Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note Gilead Sciences (GILD) concluded the recent trading session at $153.57, signifying a -1.88% move from its prior day''s close.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | |
| Ebit Margin | 36.8% | 5.8% | 28.8% | 24.7% | 34.0% | |
| Ebitda Margin | 46.1% | 15.4% | 38.7% | 32.4% | 41.5% | |
| Operating Profit Margin | 39.7% | 5.8% | 28.0% | 26.9% | 36.3% | |
| Pretax Profit Margin | 33.3% | 2.4% | 25.3% | 21.3% | 30.3% | |
| Continuous Operations Profit Margin | 28.9% | 1.7% | 20.7% | 16.7% | 22.7% | |
| Net Profit Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | |
| Bottom Line Profit Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | |
| Current Ratio | 1.553 | 1.597 | 1.426 | 1.285 | 1.272 | |
| Quick Ratio | 1.403 | 1.455 | 1.268 | 1.151 | 1.133 | |
| Solvency Ratio | 0.310 | 0.082 | 0.212 | 0.160 | 0.176 | |
| Cash Ratio | 0.640 | 0.832 | 0.539 | 0.482 | 0.460 | |
| Price To Earnings Ratio | 17.944 | 243.079 | 17.844 | 23.456 | 14.639 | |
| Price To Earnings Growth Ratio | 0.011 | -2.653 | 0.742 | -0.895 | 0.003 | |
| Forward Price To Earnings Growth Ratio | 0.011 | -2.653 | 0.742 | -0.895 | 0.003 | |
| Price To Earnings Diluted Ratio | 18.103 | 243.079 | 18.002 | 23.585 | 14.728 | |
| Price To Earnings Diluted Growth Ratio | 0.011 | -2.655 | 0.762 | -0.901 | 0.003 | |
| Price To Book Ratio | 6.726 | 5.959 | 4.428 | 5.073 | 4.329 | |
| Price To Sales Ratio | 5.186 | 4.006 | 3.728 | 3.949 | 3.340 | |
| Price To Free Cash Flow Ratio | 16.147 | 11.178 | 13.624 | 12.912 | 8.440 | |
| Price To Operating Cash Flow Ratio | 15.240 | 10.638 | 12.628 | 11.876 | 8.011 | |
| Debt To Assets Ratio | 0.422 | 0.453 | 0.402 | 0.399 | 0.393 | |
| Debt To Equity Ratio | 1.098 | 1.382 | 1.094 | 1.188 | 1.267 | |
| Debt To Capital Ratio | 0.523 | 0.580 | 0.523 | 0.543 | 0.559 | |
| Long Term Debt To Capital Ratio | 0.494 | 0.563 | 0.504 | 0.519 | 0.544 | |
| Financial Leverage Ratio | 2.600 | 3.052 | 2.721 | 2.974 | 3.225 | |
| Working Capital Turnover Ratio | 4.299 | 4.803 | 6.771 | 8.569 | 7.036 | |
| Operating Cash Flow Ratio | 0.848 | 0.902 | 0.710 | 0.807 | 0.981 | |
| Operating Cash Flow Sales Ratio | 0.340 | 0.377 | 0.295 | 0.333 | 0.417 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | 0.952 | 0.927 | 0.920 | 0.949 | |
| Debt Service Coverage Ratio | 3.209 | 1.513 | 3.373 | 2.370 | 3.676 | |
| Interest Coverage Ratio | 11.427 | 1.701 | 8.056 | 7.840 | 9.908 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.569 | 5.966 | 4.453 | 3.991 | 7.509 | |
| Operating Cash Flow Coverage Ratio | 0.402 | 0.405 | 0.320 | 0.360 | 0.426 | |
| Capital Expenditure Coverage Ratio | 17.796 | 20.704 | 13.685 | 12.462 | 19.661 | |
| Dividend Paid And Capex Coverage Ratio | 2.194 | 2.438 | 1.822 | 2.045 | 2.721 | |
| Dividend Payout Ratio | 0.470 | 8.162 | 0.672 | 0.808 | 0.579 | |
| Enterprise Value Multiple | 12.523 | 29.749 | 11.433 | 14.410 | 9.935 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 78.8% | ▲0.6% | ▲1.2% |
| Ebit Margin | 36.8% | ▲30.9% | ▲10.7% |
| Ebitda Margin | 46.1% | ▲30.7% | ▲11.3% |
| Operating Profit Margin | 39.7% | ▲34.0% | ▲12.4% |
| Pretax Profit Margin | 33.3% | ▲30.9% | ▲10.8% |
| Continuous Operations Profit Margin | 28.9% | ▲27.2% | ▲10.8% |
| Net Profit Margin | 28.9% | ▲27.2% | ▲10.7% |
| Bottom Line Profit Margin | 28.9% | ▲27.2% | ▲10.7% |
| Current Ratio | 1.553 | ▼-0.044 | ▲0.126 |
| Quick Ratio | 1.403 | ▼-0.052 | ▲0.121 |
| Solvency Ratio | 0.310 | ▲0.228 | ▲0.122 |
| Cash Ratio | 0.640 | ▼-0.192 | ▲0.050 |
| Price To Earnings Ratio | 17.944 | ▼-225.135 | ▼-45.448 |
| Price To Earnings Growth Ratio | 0.011 | ▲2.663 | ▲0.569 |
| Forward Price To Earnings Growth Ratio | 0.011 | ▲2.663 | ▲0.569 |
| Price To Earnings Diluted Ratio | 18.103 | ▼-224.976 | ▼-45.396 |
| Price To Earnings Diluted Growth Ratio | 0.011 | ▲2.666 | ▲0.567 |
| Price To Book Ratio | 6.726 | ▲0.767 | ▲1.423 |
| Price To Sales Ratio | 5.186 | ▲1.180 | ▲1.144 |
| Price To Free Cash Flow Ratio | 16.147 | ▲4.970 | ▲3.687 |
| Price To Operating Cash Flow Ratio | 15.240 | ▲4.602 | ▲3.561 |
| Debt To Assets Ratio | 0.422 | ▼-0.030 | ▲0.009 |
| Debt To Equity Ratio | 1.098 | ▼-0.283 | ▼-0.107 |
| Debt To Capital Ratio | 0.523 | ▼-0.057 | ▼-0.022 |
| Long Term Debt To Capital Ratio | 0.494 | ▼-0.069 | ▼-0.031 |
| Financial Leverage Ratio | 2.600 | ▼-0.452 | ▼-0.315 |
| Working Capital Turnover Ratio | 4.299 | ▼-0.504 | ▼-1.997 |
| Operating Cash Flow Ratio | 0.848 | ▼-0.054 | ▼-0.001 |
| Operating Cash Flow Sales Ratio | 0.340 | ▼-0.036 | ▼-0.012 |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | ▼-0.008 | ▲0.005 |
| Debt Service Coverage Ratio | 3.209 | ▲1.696 | ▲0.381 |
| Interest Coverage Ratio | 11.427 | ▲9.726 | ▲3.640 |
| Short Term Operating Cash Flow Coverage Ratio | 3.569 | ▼-2.397 | ▼-1.528 |
| Operating Cash Flow Coverage Ratio | 0.402 | ▼-0.004 | ▲0.019 |
| Capital Expenditure Coverage Ratio | 17.796 | ▼-2.908 | ▲0.934 |
| Dividend Paid And Capex Coverage Ratio | 2.194 | ▼-0.244 | ▼-0.050 |
| Dividend Payout Ratio | 0.470 | ▼-7.692 | ▼-1.668 |
| Enterprise Value Multiple | 12.523 | ▼-17.226 | ▼-3.087 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $152.69B | $115.19B | $101.10B | $107.74B | $91.20B | |
| Enterprise value | $170.06B | $131.91B | $120.00B | $127.56B | $112.56B | |
| EV / Sales | 5.78x | 4.59x | 4.43x | 4.68x | 4.12x | |
| EV / Op. cash flow | 16.97x | 12.18x | 14.99x | 14.06x | 9.89x | |
| EV / Free cash flow | 17.98x | 12.80x | 16.17x | 15.29x | 10.42x | |
| EV / EBITDA | 12.52x | 29.75x | 11.43x | 14.41x | 9.94x | |
| Net debt / EBITDA | 1.28x | 3.77x | 1.80x | 2.24x | 1.89x | |
| Current ratio | 1.55x | 1.60x | 1.43x | 1.28x | 1.27x | |
| Income quality | 1.18x | 22.56x | 1.41x | 1.98x | 1.84x | |
| Graham number | $53 | $12 | $43 | $37 | $43 | |
| Graham net-net | -$18 | -$19 | -$22 | -$25 | -$29 | |
| Tax burden | 86.9% | 69.6% | 82.6% | 79.0% | 75.2% | |
| Interest burden | 90.5% | 41.4% | 87.9% | 86.1% | 89.2% | |
| Working capital | $6.53B | $7.17B | $4.80B | $3.21B | $3.16B | |
| Invested capital | $37.43B | $40.84B | $44.89B | $45.89B | $50.07B | |
| Return on assets | 14.4% | 0.8% | 9.1% | 7.3% | 9.2% | |
| Operating ROA | 19.8% | 2.7% | 12.1% | 11.2% | 14.5% | |
| Return on tangible assets | 25.2% | 1.6% | 20.7% | 17.7% | 23.8% | |
| Return on equity | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% | |
| Return on invested capital | 20.3% | 2.4% | 11.8% | 10.6% | 12.8% | |
| Return on capital employed | 24.8% | 3.5% | 15.0% | 14.1% | 17.6% | |
| Earnings yield | 5.6% | 0.4% | 5.6% | 4.3% | 6.8% | |
| Free cash flow yield | 6.2% | 8.9% | 7.3% | 7.7% | 11.8% | |
| Capex / Op. cash flow | 5.6% | 4.8% | 7.3% | 8.0% | 5.1% | |
| Capex / Depreciation | 20.4% | 18.9% | 21.7% | 34.6% | 28.2% | |
| Capex / Sales | 1.9% | 1.8% | 2.2% | 2.7% | 2.1% | |
| SG&A / Sales | 19.4% | 21.2% | 22.5% | 20.8% | 19.2% | |
| R&D / Sales | 19.7% | 20.5% | 21.1% | 18.2% | 16.9% | |
| Stock comp / Sales | 3.0% | 2.9% | 2.8% | 2.4% | 2.3% | |
| Intangibles / Total assets | 42.9% | 47.9% | 56.0% | 58.9% | 61.5% | |
| Days sales outstanding | 61d | 56d | 63d | 64d | 60d | |
| Days payables outstanding | 42d | 49d | 31d | 58d | 39d | |
| Operating cycle | 165d | 156d | 163d | 161d | 150d | |
| Cash conversion cycle | 123d | 107d | 132d | 103d | 111d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years